Wikipedia

Elsulfavirine

Elsulfavirine (trade name Elpida; also known as VM 1500) is drug used to treat HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI).[1][2][3] Elsulfavirine is a prodrug which is metabolized to the active antiviral agent deselsulfavirine (also known as VM 1500A).[4] It was developed by the Russian company Viriom.[5]

Elsulfavirine
Clinical data
Trade namesElpida
Other namesVM 1500; elpivirine
ATC code
  • None
Legal status
Legal status
  • Rx-only in Russia
Identifiers
  • N-[4-[[2-[4-Bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetyl]amino]-3-chlorophenyl]sulfonylpropanamide
CAS Number
PubChem CID
DrugBank
UNII
Chemical and physical data
FormulaC24H17BrCl2FN3O5S
Molar mass629.28 g·mol−1
  • InChI=1S/C24H17BrCl2FN3O5S/c1-2-21(32)31-37(34,35)17-4-6-20(19(27)11-17)30-22(33)9-14-3-5-18(25)24(23(14)28)36-16-8-13(12-29)7-15(26)10-16/h3-8,10-11H,2,9H2,1H3,(H,30,33)(H,31,32)
  • Key:ULTDEARCBRNRGR-UHFFFAOYSA-N

In June 2017, elsulfavirine was approved for use in Russia as an oral formulation for the treatment of HIV-1 infections in combination with other antiretroviral drugs.[4][6] Currently, elsulfavirine is used in antiretroviral therapy regimens in the Russian Federation, which includes the combination elsulfavirine + lamivudine (or emtricitabine) + tenofovir.[7]

Long-acting injectable formulations of eslulfavarinin and deselsulfavarine are under investigation.[8][9]

In addition, Roche is investigating the use of elsulfavirin for the treatment of COVID-19 and it is currently in Phase II clinical trials for this possible indication.[5]

References

edit
  1. ^ Wang Y, De Clercq E, Li G (October 2019). "Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment". Expert Opinion on Drug Metabolism & Toxicology. 15 (10): 813–829. doi:10.1080/17425255.2019.1673367. PMID 31556749. S2CID 203439476.
  2. ^ Rai MA, Pannek S, Fichtenbaum CJ (June 2018). "Emerging reverse transcriptase inhibitors for HIV-1 infection". Expert Opinion on Emerging Drugs. 23 (2): 149–157. doi:10.1080/14728214.2018.1474202. PMC 6158299. PMID 29737220.
  3. ^ Wang Y, De Clercq E, Li G (October 2019). "Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment". Expert Opinion on Drug Metabolism & Toxicology. 15 (10): 813–829. doi:10.1080/17425255.2019.1673367. PMID 31556749. S2CID 203439476.
  4. ^ a b Al-Salama ZT (October 2017). "Elsulfavirine: First Global Approval". Drugs. 77 (16): 1811–1816. doi:10.1007/s40265-017-0820-3. PMID 28940154. S2CID 25316512.
  5. ^ a b "Elsulfavirine - Viriom". AdisInsight.
  6. ^ Bolger CA, Carpenter JE, Dhar TG, Pashine A, Dragovich PS, Cook JH, Gillis EP, Peese KM, Merritt JR. "Chapter 29: To Market, To Market--2017". 2018 Medicinal Chemistry Reviews. 53.
  7. ^ "Elpida (elsulfavirine) becomes the preferred first line therapy for treatment of HIV infection in Russia" (Press release). PRN Newswire. February 2, 2021.
  8. ^ Akram R, DeSimone Jr J (June 5, 201). "What's in the Pipeline?". Contagion. 4 (3).
  9. ^ Bichko V, Rogovoy B, Koryakova A (2017). "Pre-clinical pharmacokinetics of elsufavirine/VM1500A long acting injectable formulations". International Antiviral Society-USA. Poster WEPEA0190.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Elsulfavirine&oldid=1241127326"